findmyKOL
Clinical trialNCT00843375RecruitingObservational

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

SponsorUniversity of Michigan Rogel Cancer CenterEnrollment1,200Colonic Neoplasms
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Flinders Medical Center

    Adelaide, South Australia, Australia

    Graeme Young, MD, MBBS
    Recruiting
Canada
  • St. Michael'S Hospital

    Toronto, Ontario, Canada

    Withdrawn
United States
  • Cedars-Sinai Medical Center

    Los Angeles, California, United States

    Recruiting
  • Carle Cancer Center

    Urbana, Illinois, United States

    Completed
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Sapna Syngal, MD
    Recruiting
  • University of Michigan

    Ann Arbor, Michigan, United States

    Elena Stoffel, MD
    Recruiting
  • University of Minnesota

    Minneapolis, Minnesota, United States

    Tim Church, MD
    Recruiting
  • Nyu Langone Health

    New York, New York, United States

    Aasma Shaukat, MD
    Recruiting
  • University of North Carolina

    Chapel Hill, North Carolina, United States

    Completed
  • Oregon Health and Science University

    Portland, Oregon, United States

    Recruiting
  • Hershey Medical Center

    Hershey, Pennsylvania, United States

    Completed
  • M.D. Anderson Cancer Center

    Houston, Texas, United States

    Robert Bresalier, MD
    Recruiting
  • University of Washington

    Seattle, Washington, United States

    William Grady, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Aug 2019
Primary completion
31 Mar 2028
Completion
31 Mar 2028
Last update posted
11 May 2026
Registered enrollment
1,200
Registry id
NCT00843375

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.